{"id":66327,"date":"2026-05-26T14:28:38","date_gmt":"2026-05-26T06:28:38","guid":{"rendered":"https:\/\/flcube.com\/?p=66327"},"modified":"2026-05-26T14:28:39","modified_gmt":"2026-05-26T06:28:39","slug":"microport-neurotech-secures-fda-approval-for-numen-helia-spring-coil-system-advanced-solution-for-complex-neurovascular-lesions","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66327","title":{"rendered":"MicroPort NeuroTech Secures FDA Approval for NUMEN Helia Spring Coil System \u2013 Advanced Solution for Complex Neurovascular Lesions"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>MicroPort NeuroTech Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2172:HKG\">HKG: 2172<\/a>) announced it has received <strong>marketing approval from the U.S. Food and Drug Administration (FDA)<\/strong> for its <strong>NUMEN Helia spring coil embolization system<\/strong>, indicated for <strong>endovascular occlusion or blockage of neurovascular abnormalities<\/strong> to interrupt blood flow in complex vascular lesions.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>FDA (United States)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>510(k) clearance \/ PMA approval<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>NUMEN Helia spring coil embolization system<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Endovascular occlusion of neurovascular abnormalities to interrupt blood flow<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>May 2026<\/td><\/tr><tr><td><strong>Market Entry<\/strong><\/td><td>Immediate commercial availability in the United States<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-innovation-amp-technical-specifications\" class=\"wp-block-heading\">Product Innovation &amp; Technical Specifications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Evolution:<\/strong> Enhanced iteration of the established <strong>NUMEN series coil products<\/strong><\/li>\n\n\n\n<li><strong>Key Differentiators:<\/strong> &#8220;<strong>Longer, thinner, and softer<\/strong>&#8221; design characteristics<\/li>\n\n\n\n<li><strong>Microcatheter Compatibility:<\/strong> Specifically engineered for <strong>0.013-inch microcatheters<\/strong><\/li>\n\n\n\n<li><strong>Clinical Advantages:<\/strong><\/li>\n\n\n\n<li>Optimized for <strong>small, tortuous, or access-limited vessels<\/strong><\/li>\n\n\n\n<li>Enhanced navigability through complex vascular anatomy<\/li>\n\n\n\n<li>Improved conformability to irregular aneurysm shapes<\/li>\n\n\n\n<li>Reduced risk of vessel injury during deployment<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature Comparison<\/th><th>NUMEN Series (Existing)<\/th><th>NUMEN Helia (New)<\/th><\/tr><\/thead><tbody><tr><td><strong>Length<\/strong><\/td><td>Standard lengths<\/td><td><strong>Extended lengths<\/strong><\/td><\/tr><tr><td><strong>Diameter<\/strong><\/td><td>Standard profiles<\/td><td><strong>Thinner profiles<\/strong><\/td><\/tr><tr><td><strong>Softness<\/strong><\/td><td>Standard flexibility<\/td><td><strong>Enhanced softness<\/strong><\/td><\/tr><tr><td><strong>Microcatheter Compatibility<\/strong><\/td><td>0.0165-inch+<\/td><td><strong>0.013-inch<\/strong><\/td><\/tr><tr><td><strong>Target Vessels<\/strong><\/td><td>Standard anatomy<\/td><td><strong>Small, tortuous, access-limited vessels<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-application-amp-market-opportunity\" class=\"wp-block-heading\">Clinical Application &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market Segment<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Target Indications<\/strong><\/td><td>Cerebral aneurysms, arteriovenous malformations (AVMs), other neurovascular abnormalities<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Estimated 30,000-40,000 annual endovascular coiling procedures in the US<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Competes with Stryker&#8217;s Target coils, Medtronic&#8217;s Axium coils, and Terumo&#8217;s MicroVention portfolio<\/td><\/tr><tr><td><strong>Differentiation Strategy<\/strong><\/td><td>Superior performance in challenging anatomies where standard coils face delivery limitations<\/td><\/tr><tr><td><strong>Pricing Position<\/strong><\/td><td>Premium pricing justified by enhanced technical capabilities and improved procedural outcomes<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA approval positions NUMEN Helia as a specialized solution for interventional neuroradiologists treating complex cases that previously required multiple devices or alternative approaches.<\/p>\n\n\n\n<h2 id=\"h-strategic-impact-amp-commercial-outlook\" class=\"wp-block-heading\">Strategic Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>US Market Penetration:<\/strong> FDA approval provides access to the world&#8217;s largest neurovascular market (estimated $1.2B annually)<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Success in the US regulatory pathway facilitates CE Mark and other international approvals<\/li>\n\n\n\n<li><strong>Portfolio Enhancement:<\/strong> Strengthens MicroPort NeuroTech&#8217;s position as a comprehensive neurovascular solutions provider<\/li>\n\n\n\n<li><strong>Revenue Contribution:<\/strong> Expected to contribute meaningfully to international revenue growth starting Q4 2026<\/li>\n\n\n\n<li><strong>Clinical Adoption:<\/strong> Initial launch focused on high-volume neurointerventional centers with complex case volumes<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market penetration, revenue expectations, and commercial performance. Actual results may differ due to risks including market adoption rates, competitive dynamics, reimbursement challenges, and regulatory compliance requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052500020_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026052500020_c.\"><\/object><a id=\"wp-block-file--media-46be4639-fb77-40d7-b9d3-c13979836f81\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052500020_c.pdf\">2026052500020_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052500020_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-46be4639-fb77-40d7-b9d3-c13979836f81\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MicroPort NeuroTech Limited (HKG: 2172) announced it has received marketing approval from the U.S. Food&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[1462,1461,15],"class_list":["post-66327","post","type-post","status-publish","format-standard","hentry","category-company","category-medical-device","tag-hkg-2172","tag-microport-neurotech","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MicroPort NeuroTech Secures FDA Approval for NUMEN Helia Spring Coil System \u2013 Advanced Solution for Complex Neurovascular Lesions - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"MicroPort NeuroTech Limited (HKG: 2172) announced it has received marketing approval from the U.S. Food and Drug Administration (FDA) for its NUMEN Helia spring coil embolization system, indicated for endovascular occlusion or blockage of neurovascular abnormalities to interrupt blood flow in complex vascular lesions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66327\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MicroPort NeuroTech Secures FDA Approval for NUMEN Helia Spring Coil System \u2013 Advanced Solution for Complex Neurovascular Lesions\" \/>\n<meta property=\"og:description\" content=\"MicroPort NeuroTech Limited (HKG: 2172) announced it has received marketing approval from the U.S. Food and Drug Administration (FDA) for its NUMEN Helia spring coil embolization system, indicated for endovascular occlusion or blockage of neurovascular abnormalities to interrupt blood flow in complex vascular lesions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66327\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-26T06:28:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-26T06:28:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66327#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66327\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MicroPort NeuroTech Secures FDA Approval for NUMEN Helia Spring Coil System \u2013 Advanced Solution for Complex Neurovascular Lesions\",\"datePublished\":\"2026-05-26T06:28:38+00:00\",\"dateModified\":\"2026-05-26T06:28:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66327\"},\"wordCount\":411,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 2172\",\"MicroPort NeuroTech\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66327#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66327\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66327\",\"name\":\"MicroPort NeuroTech Secures FDA Approval for NUMEN Helia Spring Coil System \u2013 Advanced Solution for Complex Neurovascular Lesions - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-26T06:28:38+00:00\",\"dateModified\":\"2026-05-26T06:28:39+00:00\",\"description\":\"MicroPort NeuroTech Limited (HKG: 2172) announced it has received marketing approval from the U.S. Food and Drug Administration (FDA) for its NUMEN Helia spring coil embolization system, indicated for endovascular occlusion or blockage of neurovascular abnormalities to interrupt blood flow in complex vascular lesions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66327#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66327\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66327#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MicroPort NeuroTech Secures FDA Approval for NUMEN Helia Spring Coil System \u2013 Advanced Solution for Complex Neurovascular Lesions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MicroPort NeuroTech Secures FDA Approval for NUMEN Helia Spring Coil System \u2013 Advanced Solution for Complex Neurovascular Lesions - Insight, China&#039;s Pharmaceutical Industry","description":"MicroPort NeuroTech Limited (HKG: 2172) announced it has received marketing approval from the U.S. Food and Drug Administration (FDA) for its NUMEN Helia spring coil embolization system, indicated for endovascular occlusion or blockage of neurovascular abnormalities to interrupt blood flow in complex vascular lesions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66327","og_locale":"en_US","og_type":"article","og_title":"MicroPort NeuroTech Secures FDA Approval for NUMEN Helia Spring Coil System \u2013 Advanced Solution for Complex Neurovascular Lesions","og_description":"MicroPort NeuroTech Limited (HKG: 2172) announced it has received marketing approval from the U.S. Food and Drug Administration (FDA) for its NUMEN Helia spring coil embolization system, indicated for endovascular occlusion or blockage of neurovascular abnormalities to interrupt blood flow in complex vascular lesions.","og_url":"https:\/\/flcube.com\/?p=66327","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-26T06:28:38+00:00","article_modified_time":"2026-05-26T06:28:39+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66327#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66327"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MicroPort NeuroTech Secures FDA Approval for NUMEN Helia Spring Coil System \u2013 Advanced Solution for Complex Neurovascular Lesions","datePublished":"2026-05-26T06:28:38+00:00","dateModified":"2026-05-26T06:28:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66327"},"wordCount":411,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 2172","MicroPort NeuroTech","Product approvals"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66327#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66327","url":"https:\/\/flcube.com\/?p=66327","name":"MicroPort NeuroTech Secures FDA Approval for NUMEN Helia Spring Coil System \u2013 Advanced Solution for Complex Neurovascular Lesions - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-26T06:28:38+00:00","dateModified":"2026-05-26T06:28:39+00:00","description":"MicroPort NeuroTech Limited (HKG: 2172) announced it has received marketing approval from the U.S. Food and Drug Administration (FDA) for its NUMEN Helia spring coil embolization system, indicated for endovascular occlusion or blockage of neurovascular abnormalities to interrupt blood flow in complex vascular lesions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66327#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66327"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66327#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MicroPort NeuroTech Secures FDA Approval for NUMEN Helia Spring Coil System \u2013 Advanced Solution for Complex Neurovascular Lesions"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66327","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66327"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66327\/revisions"}],"predecessor-version":[{"id":66330,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66327\/revisions\/66330"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66327"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66327"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}